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To the Editor:
Recent therapeutic advances for mantle cell lymphoma
(MCL) include inhibitors of Bruton’s tyrosine kinase
(BTK), a critical component in the B-cell receptor signaling
pathway [1, 2]. Remarkably, approximately two thirds of
patients with relapsed/refractory (R/R) MCL treated with
ibrutinib, the ﬁrst-in-class BTK inhibitor, achieve a durable
response [3–5]. However, ibrutinib treatment also com-
monly produces off-target adverse events (AEs) such as
bleeding, atrial ﬁbrillation, diarrhea, and infection.
Second-generation BTK inhibitors with greater selectiv-
ity include tirabrutinib (GS/ONO-4059), acalabrutinib, and
BGB-3111 [6]. In 2017, acalabrutinib received FDA
approval for the treatment of MCL based on a complete
response (CR) rate of 40% and an overall response rate
(ORR) of 81% at a median follow-up of 15.2 months in a
phase 2 study [7]. Tirabrutinib has demonstrated signiﬁcant
activity without major drug-related toxicities in a phase
1 study in R/R B-cell malignancies [8] and on extended,
3-year follow-up of patients with chronic lymphocytic
leukemia [9]. Here, we provide 3-year follow-up data from
patients with MCL in the phase 1 tirabrutinib extension
study (NCT02457559).
Tirabrutinib was evaluated in six patient cohorts (at
doses ranging from 20 to 600 mg daily) with R/R B-cell
malignancies for safety and tolerability in the POE001
phase 1 clinical study (NCT01659255). Of the 90 patients
who received treatment between September 2012 and Jan-
uary 2015, those with continuing response or stable disease
were eligible for the subsequent long-term extension study
and continued at the tirabrutinib dose received in the parent
study. Once safety was established, dose increases were
permitted at the discretion of the investigator. Independent
ethics committees at each study site approved the protocol,
and all patients provided written informed consent. All
statistical analyses of safety and efﬁcacy endpoints included
all patients who were enrolled in the parent study and
received ≥1 dose of tirabrutinib. Kaplan-Meier methods
were used to analyze progression-free survival (PFS)
(the time from start of treatment until deﬁnitive
progressive disease [PD] or death). ORR (the proportion of
patients achieving CRs or partial responses [PRs]),
duration of response (DOR), and overall survival were also
assessed.
Sixteen patients with R/R MCL were enrolled in the
extension study. The median patient age was 64 years
(range 52–81); 75% of patients were male. Patients had a
median of three prior therapies (range 2–8) and ﬁve patients
(31%) had received previous transplants (n= 3 autologous
* Simon A. Rule
simon.rule@nhs.net
1 Department of Clinical Haematology, Plymouth University
Peninsula Schools of Medicine and Dentistry, Plymouth, UK
2 Department of Clinical Hematology and Unité Mixte de
Recherche–Centre National de la Recherche Scientiﬁque 5235,
Centre Hospitalier Universitaire, Université de Montpellier,
Montpellier, France
3 Cardiff Chronic Lymphocytic Leukemia Research Group, School
of Medicine, Cardiff University, Cardiff, UK
4 EA 7365 Groupe de Recherche sur les Formes Injectables et les
Technologies Associées, University of Lille, Lille, France
5 Department of Hematology, Centre Hospitalier Régional
Universitaire, Lille, France
6 Gilead Sciences, Inc, Foster City, CA, USA
7 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service
d’Hématologie, Pierre-Bénite Université de Lyon, Lyon, France
8 Ernest and Helen Scott Haematological Research Institute,
University of Leicester, Leicester, UK
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
stem-cell transplants [SCT], n= 2 allogeneic SCT). At the
time of updated analysis (May 30, 2017), ﬁve patients
remained on tirabrutinib treatment, 11 had discontinued
(nine for PD, one due to death, and one who attained a CR
on tirabrutinib but discontinued to undergo allogeneic
SCT). The median treatment duration was 97.3 weeks
(range 0–173) (Fig. 1a). ORR did not improve signiﬁcantly
with longer follow-up. At the time of updated analysis, 11
of 16 patients had responded (ORR= 68.8%), which
included 6 (55%) patients who attained a CR and 5 (45%)
who attained a PR based on standardised response criteria
[10] per investigator assessment. The median time to
response was 1.9 months (range 1.9–16.8). Responses were
durable (median DOR not reached). Estimated median PFS
was 25.8 months (Fig. 1b), and the 24-month Kaplan-Meier
estimates of PFS and overall survival were 55.6% (95% CI:
28.6, 75.9%) and 67.0% (95% CI: 37.9, 84.7%),
respectively.
No new safety or toxicity concerns were identiﬁed during
extended follow-up and tirabrutinib continued to be well
tolerated. Treatment-emergent AEs in the MCL cohort
(Table 1) most commonly included cough, diarrhea, and
thrombocytopenia, each of which occurred in seven patients
(44%).
The most common ≥Grade 3 AEs were thrombocytope-
nia (19%), anemia, (13%), neutropenia (13%), and dyspnea
(13%); most resolved in <30 days (at least 10 out of 15, 4
with dates of resolution missing). Five patients (31%)
experienced ≥Grade 3 infections (n= 2 respiratory tract
infections, n= 1 each with pneumonia, sepsis, and tooth
abscess). Grade 3 or 4 laboratory abnormalities occurring in
>1 patient included increased lymphocytes (n= 3),
Fig. 1 Duration of beneﬁt for
tirabrutinib in patients with
MCL. a Updated duration on
treatment for all patients with
MCL (n= 16) according to dose
cohort. Dose escalation was
permitted at the discretion of the
investigator after safety was
established. The assigned dose
cohort reﬂects the dose that each
patient received for the majority
of his or her treatment duration.
Asterisk (*) denotes the ﬁve
ongoing patients. Best overall
response for each patient is
shown in parentheses. Of the six
patients who attained CR, four
are ongoing in the study, 1
(#103–106) progressed, and 1
(#202–115) discontinued to
undergo allogeneic stem-cell
transplantation. Of the ﬁve
patients who attained PR, one is
ongoing in the study and four
discontinued due to PD. CR,
complete response; MCL,
mantle cell lymphoma; NR, no
response (did not reach cycle 3);
PD, progressive disease; PR,
partial response. b Updated PFS
curve for patients with MCL.
Estimated median PFS was
25.8 months. MCL, mantle cell
lymphoma; PFS, progression-
free survival.
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neutrophils (n= 3), hyponatremia (n= 2), platelets (n= 2),
and triacylglycerol lipase (n= 2).
Six patients (38%) experienced serious AEs (respiratory
tract infections, pneumonia, anemia, small intestinal
hemorrhage, general physical health deterioration, and
confusional state); none were considered related to
tirabrutinib.
In this long-term follow-up study, no patient dis-
continued due to an AE. In contrast, with long-term follow-
up (median, 26.7 months) in a study of ibrutinib in R/R
MCL, 11% of patients had discontinued ibrutinib due to
AEs. This study also found that ibrutinib was associated
with atrial ﬁbrillation (11%) and bleeding events (50%, 6%
of which were ≥Grade 3) [4]. No cases of atrial ﬁbrillation
were observed in our study of tirabrutinib or in the aca-
labrutinib phase 2 study in R/R MCL [7]. Grade 3 or higher
bleeding events were infrequent, with Grade 3 gastro-
intestinal hemorrhage observed in 1 tirabrutinib-treated
patient (present study) and 1 acalabrutinib-treated patient
[7]. Although our sample size was small (n= 16 R/R MCL
patients treated with tirabrutinib), headache was a less fre-
quent AE in our study of tirabrutinib (two patients [13%])
than in the phase 2 study of acalabrutinib (47 patients [38%]
[7]). The rate of diarrhea was 44% in our study of tir-
abrutinib and 38% in the study of acalabrutinib [7].
Pooled analyses of ibrutinib-treated R/R MCL patients
have shown that better clinical outcomes were associated with
fewer prior lines of therapy [11, 12]. ORRs were 73% for
ibrutinib-treated patients with just 1 prior line of therapy
(n= 99) and 62% for those with ≥3 prior lines (n= 162) at
24-month follow-up [11], and median PFS was 33.6 months
for patients with just 1 prior line of therapy compared to
8.4 months for patients with ≥2 prior lines of therapy at 3.5
years of follow-up [12]. In this 3-year follow-up of tir-
abrutinib in heavily pretreated R/R MCL patients (63% of
patients had received ≥3 prior lines of therapy), ORR was
69% and median PFS was 25.8 months, supporting persistent,
robust efﬁcacy and safety of tirabrutinib even after multiple
lines of therapy in the R/R setting. In conclusion, tirabrutinib
demonstrated a favorable long-term safety and efﬁcacy proﬁle
through extended follow-up (median, 22.3 months) in heavily
pretreated patients with R/R MCL.
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Table 1 Updated TEAEs (frequency ≥ 15%) for patients with MCL
(n= 16).
AE, n (%) Grade 1–2 Grade ≥ 3 Total
Cough 7 (44) 0 7 (44)
Diarrhea 7 (44) 0 7 (44)
Thrombocytopenia 4 (25) 3 (19) 7 (44)
Contusion 5 (31) 0 5 (31)
Nasopharyngitis 5 (31) 0 5 (31)
Abdominal pain 4 (25) 0 4 (25)
Anemia 2 (13) 2 (13) 4 (25)
Dyspnea 2 (13) 2 (13) 4 (25)
Lower respiratory tract infection 3 (19) 1 (6) 4 (25)
Productive cough 4 (25) 0 4 (25)
Rhinitis 4 (25) 0 4 (25)
Vomiting 4 (25) 0 4 (25)
Arthralgia 3 (19) 0 3 (19)
Asthenia 3 (19) 0 3 (19)
Conjunctivitis 3 (19) 0 3 (19)
Lymphopenia 3 (19) 0 3 (19)
Nausea 3 (19) 0 3 (19)
Petechiae 3 (19) 0 3 (19)
Purpura 3 (19) 0 3 (19)
Rales 3 (19) 0 3 (19)
Rash, maculopapular 2 (13) 1 (6) 3 (19)
Upper respiratory tract infection 2 (13) 1 (6) 3 (19)
AE adverse event, MCL mantle cell lymphoma, TEAE treatment-
emergent AE
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